New hope for advanced colon cancer? drug combo enters phase 2 trial
NCT ID NCT07490119
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug combination for people with a certain type of advanced colorectal cancer that has not responded to prior treatments. About 31 adults will receive the drugs to see if tumors shrink and how long that lasts. The goal is to find a better option for later-line therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAS WILD TYPE MCRC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.